Merck & Co. Inc. | 2013 | FY | 3


Sales of the Company’s products were as follows:
Years Ended December 31
2013
 
2012
 
2011
Primary Care and Women’s Health
 
 
 
 
 
Cardiovascular
 
 
 
 
 
Zetia
$
2,658

 
$
2,567

 
$
2,428

Vytorin
1,643

 
1,747

 
1,882

Diabetes and Obesity
 
 
 
 
 
Januvia
4,004

 
4,086

 
3,324

Janumet
1,829

 
1,659

 
1,363

Respiratory
 
 
 
 
 
Nasonex
1,335

 
1,268

 
1,286

Singulair
1,196

 
3,853

 
5,479

Dulera
324

 
207

 
96

Asmanex
184

 
185

 
206

Women’s Health and Endocrine
 
 
 
 
 
NuvaRing
686

 
623

 
623

Fosamax
560

 
676

 
855

Follistim AQ
481

 
468

 
530

Implanon
403

 
348

 
294

Cerazette
208

 
271

 
268

Other
 
 
 
 
 
Arcoxia
484

 
453

 
431

Avelox
140

 
201

 
322

Hospital and Specialty
 
 
 
 
 
Immunology
 
 
 
 
 
Remicade
2,271

 
2,076

 
2,667

Simponi
500

 
331

 
264

Infectious Disease
 
 
 
 
 
Isentress
1,643

 
1,515

 
1,359

Cancidas
660

 
619

 
640

PegIntron
496

 
653

 
657

Invanz
488

 
445

 
406

Victrelis
428

 
502

 
140

Noxafil
309

 
258

 
230

Oncology
 
 
 
 
 
Temodar
708

 
917

 
935

Emend
507

 
489

 
419

Other
 
 
 
 
 
Cosopt/Trusopt
416

 
444

 
477

Bridion
288

 
261

 
201

Integrilin
186

 
211

 
230

Diversified Brands
 
 
 
 
 
Cozaar/Hyzaar
1,006

 
1,284

 
1,663

Primaxin
335

 
384

 
515

Zocor
301

 
383

 
456

Propecia
283

 
424

 
447

Clarinex
235

 
393

 
621

Remeron
206

 
232

 
241

Claritin Rx
204

 
244

 
314

Proscar
183

 
217

 
223

Maxalt
149

 
638

 
639

Vaccines (1)
 
 
 
 
 
Gardasil
1,831

 
1,631

 
1,209

ProQuad/M-M-R II/Varivax
1,306

 
1,273

 
1,202

Zostavax
758

 
651

 
332

Pneumovax 23
653

 
580

 
498

RotaTeq
636

 
601

 
651

Other pharmaceutical (2)
4,316

 
4,333

 
4,266

Total Pharmaceutical segment sales
37,437

 
40,601

 
41,289

Other segment sales (3)
6,325

 
6,412

 
6,428

Total segment sales
43,762

 
47,013

 
47,717

Other (4)
271

 
254

 
330

 
$
44,033

 
$
47,267

 
$
48,047

(1) 
These amounts do not reflect sales of vaccines sold in most major European markets through the Company’s joint venture, Sanofi Pasteur MSD, the results of which are reflected in Equity income from affiliates. These amounts do, however, reflect supply sales to Sanofi Pasteur MSD.
(2) 
Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(3)  
Represents the non-reportable segments of Animal Health, Consumer Care and Alliances. The Alliances segment includes revenue from the Company’s relationship with AZLP.
(4) 
Other revenues are primarily comprised of miscellaneous corporate revenues, third-party manufacturing sales, sales related to divested products or businesses and other supply sales not included in segment results. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales (see Note 3). In addition, other revenues in 2013 reflect $50 million of revenue for the out-license of a pipeline compound.

us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock